OTC · Biotechnology

Nabriva Therapeutics plc (NBRVF) Stock

$0.00 OTC: NBRVF Healthcare

Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI).

Valuation

MetricValue
Price$0.00
Market Cap$323
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-21.32
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1900.00%
ROA-178.12%
ROCE-1375.00%
Gross Margin-152.78%
Operating Margin-152.78%
Net Margin-158.33%
Debt/Equity1.67
Current Ratio1.11

Annual Financials (USD)

Metric20182019202020212022
Revenue$7.0M$8.0M$5.0M$27.0M$36.0M
Operating Profit$-114.0M$-79.0M$-66.0M$-49.0M$-55.0M
Net Profit$-115.0M$-83.0M$-69.0M$-49.0M$-57.0M
EPS$-564.91$-278.75$-135.23$-28.52$-21.32
Op Margin-1759.6%-1025.9%-1315.4%-178.3%-155.6%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$110.0M$94.0M$58.0M$81.0M$32.0M
Total Liabilities$42.0M$53.0M$25.0M$28.0M$28.0M
Cash$102.0M$86.0M$41.0M$48.0M$12.0M
Borrowings$24.0M$35.0M$8.0M$8.0M$5.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-73.0M$-72.0M$-71.0M$-60.0M$-37.0M
Investing Cash Flow$-5.0M$0$0$0$0
Financing Cash Flow$19.0M$26.0M$3.0M$38.0M$3.0M
Net Cash Flow$15.0M$-16.0M$-45.0M$6.0M$-35.0M
Free Cash Flow$-73.0M$-72.0M$-71.0M$-60.0M$-37.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.13
FCF Yield-11430959.75%
Quick Ratio0.78
Interest Coverage-79.50
Return 1Y0.00%
Return 3Y-99.99%
Return 5Y-100.00%

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Motiv8 Investments LLC 62025-12-31
Bay Harbor Wealth Management, LLC802026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCLIBrainstorm Cell Therapeutics Inc. $0.98 +6.52% -1.04 $10.81M 0.00%
CELZ $0.79 -2.09% -1.47 $2.05M 0.00%
EVFMEvofem Biosciences, Inc. $0.01 -4.76% -0.16 $1.06M 0.00%
GMVDFG Medical Innovations Holdings Ltd $0.00 — 0.00 $25992 0.00%
HEPAHepion Pharmaceuticals, Inc. $0.05 +17.78% -0.21 $617116 0.00%

About Nabriva Therapeutics plc

Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.

Nabriva Therapeutics plc (NBRVF) stock trades at $0.00 with a market capitalization of $323. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Nabriva Therapeutics plc generates a return on equity (ROE) of -1900.00%, return on capital employed of -1375.00%, an operating margin of -152.78%, a net profit margin of -158.33%.

Official website: www.nabriva.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides